Pargyline
Talk0this wiki
Assessment |
Biopsychology |
Comparative |
Cognitive |
Developmental |
Language |
Individual differences |
Personality |
Philosophy |
Social |
Methods |
Statistics |
Clinical |
Educational |
Industrial |
Professional items |
World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology
|
Pargyline chemical structure | |
| 2-[benzyl(methyl)amino]acetonitrile IUPAC name | |
| CAS number 555-57-7 | ATC code |
| PubChem 4688 | DrugBank [1] |
| Chemical formula | {{{chemical_formula}}} |
| Molecular weight | 159.23 g/mol |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Pregnancy category | |
| Legal status | |
| Routes of administration | |
Pargyline is a monoamine oxidase B (MAO-B) inhibitor. [1]
It has antihypertensive effects.[2]
Pharmacology
Edit
It functions by inhibiting the metabolism of catecholamines and tyramine within presynaptic nerve terminals. Patients taking pargyline must avoid concurrent consumption of tyramine-containing foods such as blue cheese and beer, as this can lead to a hypertensive crisis.[3]
References
Edit
- ↑ Murphy DL, Karoum F, Pickar D, et al (1998). Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). J. Neural Transm. Suppl. 52: 39–48.
- ↑ Fuentes JA, Ordaz A, Neff NH (July 1979). Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur. J. Pharmacol. 57 (1): 21–7.
- ↑ Tulane University School of Medicine Department of Pharmacology: Autonomic Drug Profile handout, October 2006
| This page uses Creative Commons Licensed content from [[Wikipedia:Pargyline | Wikipedia]] (view authors). |